托拉菌素B | 280755-12-6

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 托拉菌素B
• 中文别名: 泰拉霉素B；土拉霉素B；托拉菌素 B；妥拉霉素；土拉霉素 B；泰拉霉素 B
• 英文名称: Tulathromycin B
• 英文别名: (2R,3R,6R,8R,9R,10S,11S,12R)-2-[(2R,3R)-2,3-dihydroxypentan-2-yl]-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-8-hydroxy-11-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-5-(propylaminomethyl)oxan-2-yl]oxy-3,6,8,10,12-pentamethyl-1-oxa-4-azacyclotridecan-13-one
• CAS: 280755-12-6
• 化学式: C₄₁H₇₉N₃O₁₂
• 分子量: 806.1
• InChiKey: JEBMHQVCOAWRCT-QPTWMBCESA-N

物化性质

• 沸点：
  870.5±65.0 °C(Predicted)
• 密度：
  1.17
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  56
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.98
• 拓扑面积：
  201
• 氢给体数：
  7
• 氢受体数：
  15

制备方法与用途

用途：用于治疗由放线杆菌、支原体、巴氏杆菌和副嗜血杆菌引起的猪和牛的呼吸系统疾病。

文献信息

• [EN] PROCESS FOR PREPARATION OF TULATHROMYCIN<br/>[FR] PROCÉDÉ DE PRÉPARATION DE TULATHROMYCINE
  申请人：FARMA GRS D O O

  公开号：WO2015014907A1

  公开（公告）日：2015-02-05

  The present invention discloses a novel process for preparation of tulathromycin. The process uses fewer steps due to a more direct route without prior protection of functional groups of the compound of formula (I).

  本发明公开了一种制备图拉霉素的新工艺。该工艺由于采用了更直接的路由，无需预先保护公式(I)化合物的功能团，因此使用的步骤较少。
• [EN] IMMUNOMODULATING IMINE-OXAZOLINE AZALIDES<br/>[FR] AZALIDES IMMUNOMODULATEURS D'IMINE-OXAZOLINE
  申请人：ZOETIS SERVICES LLC

  公开号：WO2021183759A1

  公开（公告）日：2021-09-16

  Defined herein are immunemodulating Formula (1) compounds wherein R1, R2, R3, and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating an inflammatory and/or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compound of Formula (1 ) to prepare a medicament for treating an inflammatory and/or immunological disease or disorder in an animal.

  本发明定义了免疫调节式(1)化合物，其中R1、R2、R3和W如本文所定义，其立体异构体，以及药学上可接受的盐；以及包含这些化合物的组合物。本发明还包括通过给予动物治疗有效量的式(1)化合物、其立体异构体及药学上可接受的盐，来治疗炎症和/或免疫性疾病或障碍的方法；以及使用式(1)化合物制备用于治疗动物炎症和/或免疫性疾病或障碍的药物的用途。
• [EN] NEW CRYSTALLINE FORMS OF TULATHROMYCIN<br/>[FR] NOUVELLES FORMES CRISTALLINES DE TULATHROMYCINE
  申请人：FARMA GRS D O O

  公开号：WO2013013834A1

  公开（公告）日：2013-01-31

  The present invention describes new crystalline forms I, II and III of tulathromycin, new tulathromycin salts and processes for their preparation.

  本发明描述了土拉霉素的新晶体形式I、II和III，新的土拉霉素盐及其制备方法。
• IMMUNOMODULATING UREA AZALIDES
  申请人：Zoetis Services LLC

  公开号：US20210290591A1

  公开（公告）日：2021-09-23

  Defined herein are immunomodulating Formula (1) compounds wherein R, R 0 , R 1 , R 2 , R 3 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating an inflammatory and/or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compound of Formula (1) to prepare a medicament for treating an inflammatory and/or immunological disease or disorder in an animal.
• [EN] IMMUNOMODULATING O-HET-ARYL AZALIDES<br/>[FR] AZALIDES IMMUNOMODULATEURS O-HET-ARYLE
  申请人：ZOETIS SERVICES LLC

  公开号：WO2021183762A1

  公开（公告）日：2021-09-16

  Defined herein are immunomodulating Formula (1) compounds stereoisomers thereof, and pharmaceutically acceptable salts thereof; wherein R0, R1, R2, R10, W, Ring C and n are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating an inflammatory and/or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compound of Formula (1) to prepare a medicament for treating an inflammatory and/or immunological disease or disorder in an animal.